Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 28, Issue 5, Pages 839-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2014.06.006
Keywords
Multiple myeloma; Thalidomide; Lenalidomide; Bortezomib; Transplant-ineligible; Transplant-eligible; Maintenance
Categories
Funding
- Celgene
- Janssen-Cilag
- Bristol-Myers Squibb
- Millennium
- Merck
- Onyx
Ask authors/readers for more resources
Multiple myeloma (MM) is a neoplasm typical of the elderly, with median age at diagnosis of 70 years, and approximately 65% of patients older than 65 years. Many advances have been made thanks to the use of autologous hematopoietic stem cell transplantation (AHSCT) and the introduction of the immunomodulatory drugs and the proteasome inhibitors. Incorporation of novel agents into induction has resulted in improved overall survival. Optimal MM maintenance therapy should maintain or increase response after induction and, when possible, AHSCT. Optimal maintenance therapy must be effective with minimal toxicity and should be easily administered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available